Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Dyne Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapies for neuromuscular and genetic muscle diseases. Utilizing its proprietary FORCE platform, it creates conjugates of antibodies, linkers, and payloads—such as oligonucleotides and enzymes—to deliver disease-modifying treatments to muscle tissue and the CNS. Its portfolio includes therapies for DM1, DMD, FSHD, and Pompe disease, focusing on genetic targets with high unmet medical needs.
This description was generated via AI from an annual report. Updated about 1 year ago.